Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results

Prostatype Genomics
Download the release

This issue updates on the company's Medicare application in the U.S., upcoming publication of results from the completed U.S. validation study and the opportunity to watch a filmed company presentation with more information about the complementary opportunities based on the Prostatype® platform that were recently presented.

Content of the newsletter:
- Update on the company’s Medicare process and the U.S.
- U.S. Validation study by Veterans Affairs submitted for publication
- Update on billing of private insurance companies in the U.S.
- Completed investments in the U.S. puts Prostatype Genomics in a strong position
- New commercial opportunities unlocked through earlier R&D investments
- Prostatype Genomics raised SEK 11.5 million through TO5 warrant exercise

Read the full newsletter and subscribe via this link:
https://www.ii.se/en/prostatype-genomics-newsletter-november-2025/

For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com

Certified Adviser
Tapper Partners AB
Telephone: +46 (0)70 44 010 98
E-mail: ca@tapperpartners.se

About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Attachments
Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.